/
MNKD
$3.73-$0.12 (-3.12%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.2B
322M shares
52-week range
$2.23 – $6.51
35% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-0.37
Mannkind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
www.mannkindcorp.com- Employees
- 592
- IPO / List date
- Jul 28, 2004
- HQ
- DANBURY, CT
Held by traders on TradeandTell
No one on the platform currently holds MNKD.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,868,442 | $4.6M |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2017-03-03 | 1-for-5reverse |
Recent trades on TradeandTell
No one on the platform has traded MNKD yet.
